SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

Kitsada Wudhikarn; Sanam Loghavi; Abhishek A. Mangaonkar; Aref Al-Kali; Moritz Binder; Ryan Carr; Kaaren Reichard; Christy Finke; Matthew Howard; Naseema Gangat; Ayalew Tefferi; Rami Komrokji; Najla Ali; Terra Lasho; Rhett Ketterling; Eric Padron; Mrinal M. Patnaik

doi:10.1182/bloodadvances.2020003345

SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

Kitsada Wudhikarn, Sanam Loghavi, Abhishek A. Mangaonkar, Aref Al-Kali, Moritz Binder, Ryan Carr, Kaaren Reichard, Christy Finke, Matthew Howard, Naseema Gangat, Ayalew Tefferi, Rami Komrokji, Najla Ali, Terra Lasho, Rhett Ketterling, Eric Padron, Mrinal M. Patnaik

Hematology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	5716-5721
Number of pages	6
Journal	Blood Advances
Volume	4
Issue number	22
DOIs	https://doi.org/10.1182/bloodadvances.2020003345
State	Published - Nov 24 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2020003345

Cite this

Wudhikarn, K., Loghavi, S., Mangaonkar, A. A., Al-Kali, A., Binder, M., Carr, R., Reichard, K., Finke, C., Howard, M., Gangat, N., Tefferi, A., Komrokji, R., Ali, N., Lasho, T., Ketterling, R., Padron, E., & Patnaik, M. M. (2020). SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 4(22), 5716-5721. https://doi.org/10.1182/bloodadvances.2020003345

Wudhikarn, K, Loghavi, S, Mangaonkar, AA, Al-Kali, A, Binder, M, Carr, R, Reichard, K, Finke, C, Howard, M, Gangat, N, Tefferi, A, Komrokji, R, Ali, N, Lasho, T, Ketterling, R, Padron, E & Patnaik, MM 2020, 'SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival', Blood Advances, vol. 4, no. 22, pp. 5716-5721. https://doi.org/10.1182/bloodadvances.2020003345

@article{961fe753b7c149edae3ff2fa9204cad6,

title = "SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival",

author = "Kitsada Wudhikarn and Sanam Loghavi and Mangaonkar, {Abhishek A.} and Aref Al-Kali and Moritz Binder and Ryan Carr and Kaaren Reichard and Christy Finke and Matthew Howard and Naseema Gangat and Ayalew Tefferi and Rami Komrokji and Najla Ali and Terra Lasho and Rhett Ketterling and Eric Padron and Patnaik, {Mrinal M.}",

note = "Funding Information: Conflict-of-interest disclosure: M.M.P. has served on the advisory board of StemLine Pharmaceuticals. E.P. has received research funding from Kura Oncology, Incyte, and Bristol Myers Squibb and honoraria from Novartis and Taiho. The remaining authors declare no competing financial interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

day = "24",

doi = "10.1182/bloodadvances.2020003345",

language = "English (US)",

volume = "4",

pages = "5716--5721",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

AU - Wudhikarn, Kitsada

AU - Loghavi, Sanam

AU - Mangaonkar, Abhishek A.

AU - Al-Kali, Aref

AU - Binder, Moritz

AU - Carr, Ryan

AU - Reichard, Kaaren

AU - Finke, Christy

AU - Howard, Matthew

AU - Gangat, Naseema

AU - Tefferi, Ayalew

AU - Komrokji, Rami

AU - Ali, Najla

AU - Lasho, Terra

AU - Ketterling, Rhett

AU - Padron, Eric

AU - Patnaik, Mrinal M.

N1 - Funding Information: Conflict-of-interest disclosure: M.M.P. has served on the advisory board of StemLine Pharmaceuticals. E.P. has received research funding from Kura Oncology, Incyte, and Bristol Myers Squibb and honoraria from Novartis and Taiho. The remaining authors declare no competing financial interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/11/24

Y1 - 2020/11/24

UR - http://www.scopus.com/inward/record.url?scp=85097224861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097224861&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020003345

DO - 10.1182/bloodadvances.2020003345

M3 - Letter

C2 - 33216886

AN - SCOPUS:85097224861

SN - 2473-9529

VL - 4

SP - 5716

EP - 5721

JO - Blood Advances

JF - Blood Advances

IS - 22

ER -

SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this